Achieving successful delivery of oligonucleotides - From physico-chemical characterization to in vivo evaluation

Anna Scomparin, Dina Polyak, Adva Krivitsky, Ronit Satchi-Fainaro*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

39 Scopus citations

Abstract

RNA interference is one of the most promising fields in modern medicine to treat several diseases, ranging from cancer to cardiac diseases, passing through viral infections and metabolic pathologies. Since the discovery of the potential therapeutic properties of non-self oligonucleotides, it was clear that it is important to develop delivery systems that are able to increase plasma stability and bestow membrane-crossing abilities to the oligonucleotides in order to reach their cytoplasmic targets. Polymer therapeutics, among other systems, are widely investigated as delivery systems for therapeutic agents, such as oligonucleotides. Physico-chemical characterization of the supramolecular polyplexes obtained upon charge interaction or covalent conjugation between the polymeric carrier and the oligonucleotides is critical. Appropriate characterization is fundamental in order to predict and understand the in vivo silencing efficacy and to avoid undesired side effects and toxicity profile. Shedding light on the physico-chemical and in vitro requirements of a polyplex leads to an efficient in vivo delivery system for RNAi therapeutics. In this review, we will present the most common techniques for characterization of obtained polymer/oligonucleotide polyplexes and an up-to-date state of the art in vivo preclinical and clinical studies. This is the first review to deal with the difficulties in appropriate characterization of small interfering RNA (siRNA) or microRNA (miRNA) polyplexes and conjugates which limit the clinical translation of this promising technology.

Original languageEnglish
Pages (from-to)1294-1309
Number of pages16
JournalBiotechnology Advances
Volume33
Issue number6
DOIs
StatePublished - 2015

Funding

FundersFunder number
FP7/2007
Focal Technology Area
ICA-USA20150909
Rimonim Consortium
Melanoma Research Alliance302303
Leona M. and Harry B. Helmsley Charitable Trust
National Nanotechnology Initiative
Chief Scientist Office53516
European Research Council617445
Ministry of Science, Technology and Space
Israel Cancer Association
Israel Science Foundation918/14
Ministry of Industry, Trade and Labor54206
Seventh Framework Programme
Ministry for Foreign Affairs0601165111

    Keywords

    • Delivery systems
    • Nanoparticles
    • Polymer therapeutics
    • RNA interference

    Fingerprint

    Dive into the research topics of 'Achieving successful delivery of oligonucleotides - From physico-chemical characterization to in vivo evaluation'. Together they form a unique fingerprint.

    Cite this